Biomarkers and novel agents in esophago-gastric cancer: are we making progress? - Wikidata - wikimedia - TriplyDB

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

http://www.wikidata.org/entity/Q38575013

about

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

http://www.wikidata.org/entity/Q38575013

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

@en

type

label

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

@en

prefLabel

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

@en

P1433

Q38575013-3881F4B8-C23F-451F-A6CA-CCBB3CFB65BC

P1476

Q38575013-DC28D658-CD49-4CE3-916C-B449F4810091

P2093

Q38575013-4578C3CA-8F62-40A3-ADCB-AF982D7C918C

Q38575013-EA0911BA-2102-4BEE-A310-A4B7C7EEB9A4

P2860

Q38575013-04DCF87C-CA6B-425E-A192-8616713EC2F4

Q38575013-06FE9B2D-D0D7-498D-82A0-E95DFD7DB168

Q38575013-08E76ADC-6C14-4727-8B4A-94F80ABBA2EE

Q38575013-099B94BD-9646-482B-A6DF-6D556F20CBCE

Q38575013-0A6910BE-045E-4126-9A30-F9F693B48157

Q38575013-0B22AD1E-EFFE-4C13-93E2-8450175C7B32

Q38575013-0D71B5B1-DAEA-4376-9175-742134CFB27E

Q38575013-18A0FD6B-0564-4B59-AF99-0F8338AE14F9

Q38575013-1F5DB46D-DA3D-44DD-AB1E-3621F5E77CDC

Q38575013-2301558E-BB06-4319-94CB-1D7FC9851F8E

P304

Q38575013-1CD9E499-064D-4CAA-B4F0-939E1854986E

P31

Q38575013-DFEE6F97-69EE-4C9C-995D-8863833473DC

P356

Q38575013-9025B517-39CE-45BD-807B-C6DD5391BA59

P433

Q38575013-8531FAFE-92E5-45F0-BD4D-F05F3B2A003E

P478

Q38575013-068132D6-D68F-4264-A5D4-48F8D9B0890B

P577

Q38575013-213BEF90-17D0-4260-A8BC-46194FD343BA

P698

Q38575013-D8E26743-F757-441B-98FA-11FA5C5F0899

P921

Q38575013-95A79DD7-01F9-42EB-A3FB-4211E05926DA

P356

14737140.2015.1071669

P1433

Expert Review of Anticancer Therapy

P1476

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

@en

P2093

Asa Dahle-Smith

http://www.w3.org/2001/XMLSchema#string

Russell D Petty

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

Targeting the mTOR signaling pathway in neuroendocrine tumors

Exploring mechanisms of FGF signalling through the lens of structural biology

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P304

1103-1119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1071669

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26313419

http://www.w3.org/2001/XMLSchema#string

P921